Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Biallelic variants in WARS2 underlie an autosomal recessive neurodevelopmental disorder characterized by global developmental delay, ataxia, parkinsonism and lactic acidosis, designated NEMMLAS (MONDO:0060578). An 8-year-old girl presented with progressive ataxia, parkinsonism, periventricular white matter changes on MRI, elevated lactate and delayed milestones. Reanalysis of an ataxia exome panel identified homozygous NM_015836.4:c.938A>T (p.Lys313Met) in WARS2, confirmed by parental testing and prompting mitochondrial cocktail therapy, thereby expanding the phenotypic spectrum of NEMMLAS (PMID:31282308).
Functional assessment of c.938A>T in patient-derived neuroepithelial stem cells revealed mild combined complex I and IV defects, while modeling in yeast demonstrated severe respiration and viability impairment and Drosophila silencing caused lethality, consistent with a partial loss-of-function mechanism (PMID:30920170). Further reports of a recurrent hypomorphic p.Trp13Gly variant in four unrelated patients with early-onset tremor-parkinsonism responsive to levodopa support variable expressivity within WARS2-related NEMMLAS (PMID:37107582).
Key Take-home: Early and comprehensive genetic testing for WARS2 is critical for diagnosis, genotype-guided therapy, and prognosis in patients with suspected NEMMLAS.
Gene–Disease AssociationLimitedSingle unrelated proband with biallelic WARS2 mutation causing NEMMLAS and supporting functional concordance Genetic EvidenceLimitedAutosomal recessive biallelic variant in one family with confirmed segregation Functional EvidenceModerateYeast and Drosophila models and patient-derived cells demonstrate impaired mitochondrial translation and OXPHOS defects |